Abstract: A laser source attached to an ophthalmic observation instrument, such as a fundus camera, projects a spot, and a light collector is positioned in the image field of the instrument over the spot to collect return light scattered from a homogeneous tissue bed in the image field. The collected light is directed onto a photomultiplier and digitized at a sampling rate above several kHz to provide a continuous data stream which is fed to a process/control module that operates to automatically define a number n of sample intervals, select a subset of the sample intervals for analysis, transform the selected intervals, and evaluate the shape of the transformed sample intervals. The process/control module may be implemented on a simple computer, and include a user interface which indicates status of signal acquisition, selection and evaluation during a short, e.g., one-minute illumination interval.

Abstract: A method of forming microspheres containing a hydrophilic drug or agent for injection to provide localized treatment over a protracted time with sustained delivery in a therapeutically indicated rate band. The drug or agent is first dispersed or suspended as a micropulverized solid in an inert hydrophobic oil and sonicated with a non-aqueous solution of a biodegradable polymer. The dispersion is then stabilized in a second oil to remove solvent from the microspheres. Non-aqueous solvents are used throughout, and high drug concentrations are obtained simultaneously with enhanced control over a uniform and sustained delivery rate with extended duration of delivery. In vitro studies of ganciclovir in a silicone oil/fluorosilicone oil/PLGA system yield microsphere fractions that provide dose levels in a therapeutic range for CMV retinitis from only a single intravitreal injection that lasts substantially in excess of one month. The preparation method allows drug loading efficiencies above ninety percent.

Abstract: The topical application to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutic amount of an androgen or androgen analogue or a therapeutic amount of TGF-.beta. is disclosed as a method of relieving the chronic and acute manifestation of dry eye symptoms in Sjogren's syndrome. Measurement of the increased tear levels of TGF-.beta. is disclosed as a diagnostic test to monitor the therapeutic effect of topical treatment with androgen or androgen analogues.

Abstract: The topical application to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutic amount of an androgen or androgen analogue is disclosed as a method of relieving the chronic and acute manifestation of dry eye symptoms in Sj ogren's syndrome.

Abstract: The invention relates to a confocal laser imaging system and method. The system includes a laser source, a beam splitter, focusing elements, and a photosensitive detector. The laser source projects a laser beam along a first optical path at an object to be imaged, and modulates the intensity of the projected laser beam in response to light reflected from the object. A beam splitter directs a portion of the projected laser beam onto a photodetector. The photodetector monitors the intensity of laser output. The laser source can be an electrically scannable array, with a lens or objective assembly for focusing light generated by the array onto the object of interest. As the array is energized, its laser beams scan over the object, and light reflected at each point is returned by the lens to the element of the array from which it originated. A single photosensitive detector element can generate an intensity-representative signal for all lasers of the array.

Abstract: A method of treating patients suffering from aberrant conjunctival goblet cell mucous secretion associated with a disorder of or injury to the eye is disclosed. The method, which is based on the discovery that conjunctival goblet cell mucous secretion is under the control of the autonomic nervous system, includes administering to an affected eye of a patient a neural system stimulus or inhibitor for sensory, parasympathetic or sympathetic nervous system function. Also disclosed are a therapeutic composition and an article of manufacture including the therapeutic composition useful for carrying out the method of the invention.

Abstract: An optical concentrator increases the power density from diffuse optical energy remitted by an optically diffusing surface by at least partially recollimating the diffuse optical energy. The concentrator includes an optical diffuser element illuminated at a first point by optical input energy and remitting incident optical energy. A reflective element has a reflective surface with a concentration point located at the first point and the reflective surface reflects diffuse optical energy incident on it from the diffuser element. At least one aperture is provided for the transmission of an output beam formed by a portion of the diffuse optical energy from at least the diffuser element.